Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Dry Eye
- Dry Eye Syndromes
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Subjects will be randomized in a 1:1 ratio RGN-259 to placebo ophthalmic solution.Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: All subjects, investigators, and study personnel involved with the conduct of the study will be masked with regard to treatment assignments.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03937882
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon